Patient must be >= 18 years and =< 39 years of age at registration

Patient must have a histologically confirmed diagnosis of primary cancer of any stage within 12 weeks (84 days) at registration

Patient must not have a recurrence or second primary cancer

Patients must not have basal cell skin carcinoma

Patient must have received, be currently receiving or planning to receive treatment for cancer, including surgery and/or chemotherapy and/or radiation therapy

Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-3

Patient must have a life expectancy > 24 months

Patient must be able to complete questionnaires in English or in Spanish

Patient must have internet access through computer, tablet, or smartphone

Patient must have an email address

Patient must have a mobile phone able with text messaging capabilities

Patient must be able to accurately provide self-report data (e.g. per clinical judgment, cognitive function is intact)

Patient must be able to provide informed consent

Participation in clinical trials is not an exclusionary criterion in EAQ202. Patients may be dually enrolled in EAQ202 as well as in therapeutic trials, including those involving checkpoint inhibitors
* NOTE: We understand that some therapeutic trials may also collect PRO data (e.g., the cross-National Clinical Trials Network [NCTN] S1826 study in which ECOG-ACRIN is participating), thus creating a potential for overburdening patients. We will be attentive to informing all patients of this potential overburdening as they consider a voluntary decision to register for EAQ202. We will coordinate with the PRO chair(s) of the therapeutic studies to ensure that the integrity of the PRO analyses be preserved

PRIMARY OBJECTIVE:
I. To evaluate feasibility and acceptability of completing patient reported outcomes (PROs) among AYAs randomized to Choice PRO versus (vs) Fixed PRO.

EXPLORATORY OBJECTIVES:
I. To evaluate AYAs’ health-related quality of life (HRQOL) priorities and HRQOL PRO trajectories.
II. To evaluate access to and utilization of psychosocial and financial resources using items from the Consumer-Based Cancer Care Value Index (CCVI).
III. To summarize AYAs’ preferences for how their PRO data should be shared with them, their families, and/or their providers.

OUTLINE: Patients are randomized to 1 of 2 arms. 

ARM I (CHOICE PRO): Patients rank 15 HRQOL domains from most important to least important and choose 5 HRQOL domains to complete over 13-18 minutes at baseline, 1, 3, 6 and 12 months.

ARM II (FIXED PRO): Patients rank 15 HRQOL domains from most important to least important and complete 5 pre-selected HRQOL domains over 13-18 minutes at baseline, 1, 3, 6 and 12 months.